Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RXI is an illiquid stock. Price movement on tiny volume (3% decline on 15k shares traded today) is meaningless.
Meaning you basically can't sell your shares in a single transaction without taking a substantial haircut. The only practical way is to use a limit order.
So far as whether the Nov CC will say anything meaningful - especially in the way of positive financial news - is not something I'm banking on. Note that the poster presentations (available on RXI's website) are pretty repetitive, with new info doled out very meagerly. Sort of like watching paint dry.
We really have no idea when / if deals will occur.
While it's heartening that no insiders have resigned, there have also been no insider purchases. I guess that so long as salaries are paid, research will continue.
I have all of 2000 shares so there's not much point in trying to sell out now. I will hang on until either RXI fails or catches the Brass Ring. This Chinese water torture will hopefully end in a few months, one way or the other.
Correct.
At this point, RXI has been making numerous presentations for years. The only deals have been with MirImmune and Thera Neuropharma - two very tiny, very early-stage biotechs. Those companies won't be bringing home the bacon anytime soon.
So far as Big Pharma doing a deal, I think they want to see positive test results first. Deals like Pfizer's 2011 purchase of Excaliard - and subsequent failure of Excaliard's anti-scarring drug (targeting CTGF) - does not bode well for RXI. "Once bitten, twice shy" applies here.
1) "In Cavendish Global Health Impact Forum news it did not mention there would have news after Forum."
You're parsing the news too closely. The presentation will be posted.
2) "Maybe if the three companies merged, there will be a major investment company willing to give money?"
Merging three financially-weak companies would simply make a larger financially-weak company that would also be more complicated to evaluate. RXI has multiple Phase 2 clinical tests in progress. The other companies are in the preclinical / discovery phase. In other words, they aren't worth much at the moment.
1) Will RXI merge with MirImmune, Inc. or Thera Neuropharma, Inc.?"
I certainly hope not. Both MirImmune and Thera Neuropharma are privately held, which means they have little money (which, in turn, is RXI's major challenge).
2) Why do you say, "there will be no news released after the Forum"?
Generally, presentations are posted on RXI's website
Click "Investors ==> Presentations & Posters".
You can even see the latest presentation:
9/14/2016
BioPharm America International Partnering Conference
Which means what?
And what does it mean for a thinly-traded / illiquid company, that is event-driven (ie, either the drugs work or they don't), that is literally months away from being out of money?
This protest will NOT be a problem.
==================================
From seekingalpha:
I'm not unsympathetic to genuine concerns about sacred grounds, but it seems clear that the tribe had no interest in engaging with federal authorities or ETP to help identify potential areas of concern - see link to AP article that gives some of the background to the Judge's ruling
http://apne.ws/2crZh9f
The Other Guy, you could have also simply contacted Investor Relations:
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
And East Texas, how in the world did you stumble upon this commercial Real Estate listing? Pretty obscure. You would do well with the FBI or CIA.
RXI's address is:
257 Simarano Dr Ste 101
Note the "Ste 1". The ad you doesn't state whether the available space is for the entire building or not.
Considering RXI's major concerns (funding and test results), you might be jumping to conclusions a bit too hastily.
"Big hands lower the price and take out stop loss?"
No! Much, much worse:
Nobody (and I mean nobody) is interested in RXI.
All of 42K shares traded today, of which it looks like about 30K shares traded near the close (and keep in mind 42K shares translates to all of $86,000). Hardly the stuff of the Big Money / Big Hands bogeyman.
You want to be a Master of the Universe (at least, so far as RXI is concerned)? Well, just place a 1,000-share order and you'll see the bid / ask move.
Forget about paranoid fantasies / conspiracies of them manipulating the price (especially so-called insiders who have shown scant interest in RXI for years). RXI is dead money at the moment.
Can't say for sure but feels like it's been run down "shaking off" the "weak hands."
============================
I just can't resist: Curb your enthusiasm.
You do realize that trope has been trotted out for literally YEARS regarding RXI's prospects, don't you?
That if you bought shares two years ago, you're looking at a 90+% loss (yes, paper losses are real losses).
I'm long, btw, but to regard RXI as anything other than highly speculative (sporting an absolutely dismal record of "investor value") is folly. The frustrating thing about RXI is that while good technical progress is being made, the share price / market cap declines steadily.
Riddle me this Batman:
What does smart money (such as insiders) know that we don't?
RXI (and virtually all R&D biotechs), doesn't have money to do Phase 3 testing because it costs big bucks. Talking about FDA approval is the province of Big Pharma; not small under-funded endeavors.
Realistically, RXI's path to continued existence lies with the cosmeceuticals. Maybe also with Samcyprone if the Phase 2 results are impressive.
Dermal scarring? less so.
Retinal scarring? Way, way too early in its testing.
"Short Interest as of 8/15 dropped another 9,000 to 92,343. ... Nothing to write home about. Need some news Dr. C!"
While it's true that shorting RXI has been a license to mint money (for literally years), all it takes is for one good piece of news and those investors could be squeezed out of existence. Same idea as selling naked options: great while it lasts, but every so often you get your head handed to you.
"Scarring is blockbuster -- Global market for scars is estimated $3 to $5 billion. That answers your question "
1) The market size for the cosmeceutical pipeline dwarfs all other pipelines - combined. In Asia, lighter skin is prized for the same reason as darker tanned skin is in the West: status. And name one person in the world who wouldn't want to reduce skin laxity that comes with aging.
2) The timeline for commercialization of the cosmeceuticals is far quicker than for the dermal scarring.
"Which compound is RXi's blockbuster? I guess I don't consider any of them as blockbuster, however, they are compounds that, if effective, have potential to be money makers.
Also, most companies that fall into the category have market caps of over $50 million. Risk/reward at this PPS with RXII is minimal in my opinion."
I don't want to start an argument, but I think there's some misconceptions in the post above.
1) Most / many R&D micro biotechs consider their "platform" (think of it as a scientific technology) to be their breakthrough. For RXI, it's the self-delivering RNAi (sd-RNAi). In theory, it can be used in conjunction with literally thousands of proteins / "biologics". RXI's website explains this in layman's terms.
The problem? sd-RNAi hasn't been shown to work (yet). It has not been validated. That's why getting *something* to work is so important. The licensing / partnership opportunities could be virtually limitless.
2) The biggest money drug / pipeline is the cosmeceuticals, but human testing has not begun. Many questions need to be addressed, such as,
a) How often would treatment be required?
b) Would this have to be performed by a dermatologist (increases cost), or could it be done at a skin salon (micro needling isn't exactly something you do at home)?
c) Can a topical compound be developed without requiring micro needling? So far, no success there.
d) No doubt, there are many other issues to be resolved.
3) "Risk/reward at this PPS with RXII is minimal"
Not true. At all. Just look at RXI's chart. If you bought shares as little as two years ago, you're looking at a 90+% loss. In other words, you would need a 10-bagger just to get back to even.
I've been in and out of RXI for the last 1+ years. I'm underwater probably "only" 50-60% or so (I'm afraid to tally up the actual number).
Could RXI go to zero? You betcha! Will it? No one knows.
RXI needs $10 million / year. The current market cap of $15 million precludes yet another round of dilution.
RXI needs a financial windfall, be it a merger, buyout, licensing, or partnership deal. And for that to happen, there must be nothing but good progress going forward.
IMO, a large bet ("Back up the truck!") on any stock is not a good idea. For RXI, it's a very bad move. Instead, limit yourself to no more than a 20% position. Max. If RXI is successful, you'll have your 10-bagger (and more). If not, your money will disappear. Keep in mind that, so far, RXI has been a miserable investment.
Cosmeceuticals
--------------
Human testing: duration is six months
To be begun: Before the end of 2016
Will RXI run out of money before the end of human testing? Yes. That's why the CC discussed ways to get more money (because you can't wait until all funds are completely exhausted).
On the Yahoo message board (that I now consider dead due to their "improved" format [universally reviled, btw], along with two insufferable trolls who endlessly trade insults), there was one poster, Helpme_hanna, who observed that R&D biotechs generally have:
1) The next Big Thing / Blockbuster drug in the works
2) No more than one year's worth of money
3) And are therefore very dependent on upcoming results
"I think our frustrations will be rewarded in due time."
In due time?! Are you joking?
The ophthalmology pipeline is way, way off in the future, while RXI is facing its now-standard financial drop-dead date.
That kind of long-view "visionary / pollyanish" type of "investing" is a wonderful way to lose money.
I suspect the dermal scarring pipeline has yet more Phase 2 testing in its future (specifically, Phase 2B).
The reality is that the nearer term Samcyprone and cosmeceutical pipelines had better not run into problems (so far, so good). Samcyprone seems to be getting better than expected results.
And IF the cosmeceuticals work as touted (which we'll soon see), the share price will explode.
"If the company had $20 million in cash..."
You're absolutely right. This has been RXI's situation ever since its birth. I'm long, but a rather unhappy one. What's particularly galling is the lack of insider buying (with the exception of Dr. G - who, btw, hasn't made any share purchases since April of '15).
OTOH, technical progress does seem positive (Samcyprone and the cosmeceutcals)
We'll see what we see.